Rankings · Quality
A+ companies
Graded A on the five growth-and-cash checks and strong on business quality — margins, returns and debt — which is what the plus means. Ranked by size.
48 companies meet this test
Figures as of October 1, 2026
| # | Company | Grade | Market value | Net margin | Return on capital | Revenue growth |
|---|---|---|---|---|---|---|
| 1 | LLYELI LILLY AND COMPANY | A+ | $1.12T | 33.5% | — | +39% a year |
| 2 | JNJJohnson & Johnson | A+ | $644.8B | 21.5% | 12.7% | +6% a year |
| 3 | AZNASTRAZENECA PLC | A+ | $256.5B | 16.7% | 14.5% | +11% a year |
| 4 | TMOTHERMO FISHER SCIENTIFIC INC. | A+ | $251.4B | 15.0% | 7.6% | +2% a year |
| 5 | AMGNAmgen Inc. | A+ | $229B | 23.0% | 12.4% | +13% a year |
| 6 | ISRGIntuitive Surgical, Inc. | A+ | $145.6B | 28.4% | 14.4% | +18% a year |
| 7 | MDTMedtronic plc | A+ | $111.4B | 13.9% | 6.6% | +6% a year |
| 8 | SYKSTRYKER CORP | A+ | $107B | 14.4% | 9.4% | +10% a year |
| 9 | GSKGSK plc | A+ | $106.5B | 17.5% | 19.2% | +4% a year |
| 10 | EWEdwards Lifesciences Corporation | A+ | $50.8B | 15.4% | 9.4% | +15% a year |
| 11 | VEEVVeeva Systems Inc. | A+ | $45.1B | 29.3% | 9.8% | — |
| 12 | IDXXIDEXX LABORATORIES INC /DE | A+ | $42B | 25.0% | 50.5% | +9% a year |
| 13 | ONCBEONE MEDICINES LTD. | A+ | $41.6B | 10.7% | 6.8% | +50% a year |
| 14 | ALNYALNYLAM PHARMACEUTICALS, INC. | A+ | $34B | 19.7% | 24.0% | +53% a year |
| 15 | DXCMDEXCOM, INC. | A+ | $32.7B | 20.1% | 17.6% | +16% a year |
| 16 | MTDMettler-Toledo International Inc. | A+ | $30.8B | 21.9% | — | +1% a year |
| 17 | ZTSZoetis Inc. | A+ | $29B | 27.5% | — | +5% a year |
| 18 | INCYINCYTE CORPORATION | A+ | $24.6B | 26.7% | 23.0% | — |
| 19 | THCTENET HEALTHCARE CORP | A+ | $20.8B | 14.6% | 16.2% | +3% a year |
| 20 | MEDPMedpace Holdings, Inc. | A+ | $17.4B | 17.7% | 75.7% | +18% a year |
| 21 | JAZZJazz Pharmaceuticals plc | A+ | $15.1B | 20.4% | -3.5% | +7% a year |
| 22 | EXELExelixis Inc | A+ | $14.5B | 35.3% | 31.2% | +12% a year |
| 23 | NBIXNEUROCRINE BIOSCIENCES INC | A+ | $14.1B | 20.9% | 12.6% | +26% a year |
| 24 | HALOHALOZYME THERAPEUTICS, INC. | A+ | $12.7B | 24.9% | 15.5% | +29% a year |
| 25 | GMEDGLOBUS MEDICAL, INC. | A+ | $10.2B | 17.0% | 9.1% | +42% a year |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.